← Leaderboards
Alice T Shaw
Massachusetts General Hospital
$3,731,101
Attributed
$4,762,481
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,762,481 · 4
By mechanism
R01$2,734,319 · 1
T32$685,451 · 1
K08$679,840 · 1
P50$662,871 · 1
Top collaborators
- Jeffrey A Engelman4 shared
- Daniel A. Haber2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Ben Z Stanger$14,778,829
- Sara Isabel Pai$12,404,338
- Jessica Jiyeong Lin$1,690,059
- Aaron N Hata$5,868,906
- Lecia V. Sequist$4,399,201
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant Neoplasm Of LungMalignant NeoplasmsDesignOncogenesMutationResponseIn VitroMolecularMediatingBaseMutantIn VivoPathway InteractionsNon-Small-Cell Lung CarcinomaNovel Therapeutic InterventionCessation Of LifeBiopsyCancer PatientClinical TrialsChromosomal RearrangementAnaplastic Lymphoma KinaseCancer EtiologyFuture
Grant awards (17)
Project 1$330,893
P50 · FY2025 · CA · contact PI
Project 1$331,978
P50 · FY2024 · CA · contact PI
Training Program in Cancer Biology and Therapeutics$290,832
T32 · FY2019 · CA
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$399,380
R01 · FY2018 · CA · contact PI
Training Program in Cancer Biology and Therapeutics$394,619
T32 · FY2018 · CA
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors (Diversity Supplement)$206,413
R01 · FY2018 · CA · contact PI
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$399,380
R01 · FY2017 · CA · contact PI
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$351,837
R01 · FY2016 · CA · contact PI
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$351,837
R01 · FY2015 · CA · contact PI
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$341,282
R01 · FY2014 · CA · contact PI
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$330,727
R01 · FY2013 · CA · contact PI
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$353,463
R01 · FY2012 · CA · contact PI
Ras Signaling in Development and Cancer$136,080
K08 · FY2009 · CA · contact PI
Ras Signaling in Development and Cancer$136,080
K08 · FY2008 · CA · contact PI
Ras Signaling in Development and Cancer$136,080
K08 · FY2007 · CA · contact PI
Ras Signaling in Development and Cancer$136,080
K08 · FY2006 · CA · contact PI
Ras Signaling in Development and Cancer$135,520
K08 · FY2005 · CA